Please follow our latest Press Releases and News Articles. Click headlines below to read full stories and access to the original articles

October 9, 2020

Branford BioMed Company Develops Handheld, Rapid COVID-19 Test

BRANFORD, CT — Tangen Biosciences, a molecular diagnostics company in Branford, has created a portable, handheld rapid testing device called Gene Spark that can detect the virus that causes COVID-19, among many other pathogens. Tangen co-founder and chief scientific officer John Davidson said the biosciences company has created the “perfect tool to fight the Covid …

September 30, 2020

Murphy Highlights Branford Innovator Tangen As “Murphy’s Innovator Of The Month”

HARTFORD—U.S. Senator Chris Murphy (D-Conn.) announced on Wednesday that innovator Tangen Biosciences in Branford has been named “Innovator of the Month.” Founded in 2013 by two Connecticut natives, Tangen’s goal has been to bring high quality molecular diagnostics for infectious diseases out of the laboratory and closer to the patient, including remote, rural, and underserved communities. Tangen has developed a …

September 15, 2020

Branford Company Makes Medical Testing Device That Can Deliver COVID Results in Minutes

BRANFORD, Conn. (WTNH) — The fight to stop the spread of COVID-19 keeps being hampered by the fact that COVID-19 tests take days to come back from a lab. But one Branford company has a device that can deliver an accurate reading in just a few minutes. Tangen Biosciences opened up in 2013 to make …

August 6, 2020

Tangen Biosciences Closes Oversubscribed $12.2M Series B Preferred Stock Financing

BRANFORD, Conn.–(BUSINESS WIRE)–Tangen Biosciences, Inc., a molecular diagnostic company located in Branford, Connecticut, announced that it has closed a $12.2 million Series B Preferred Stock financing with participation of current and new investors, including Connecticut Innovations, VC23, Leading Edge Ventures, and Parvizi Surgical. The financing was oversubscribed from the $10 million initially sought to be …

June 29, 2020

Tangen Biosciences Awarded a Contract for Point-of-Care Detection of Candida auris

BRANFORD, Conn.–(BUSINESS WIRE)–Tangen Biosciences, Inc. announced today that it was awarded a contract by the New York State Department of Health’s Wadsworth Center in conjunction with Health Research Inc. to develop a point-of-care device for detection of Candida auris, a “superbug” that is resistant to anti-fungal drugs and is emerging as a public health threat. According to …

May 29, 2020

Tangen Biosciences and LabWare Formed an Exclusive Partnership for Point-of-Care COVID-19 Molecular Test and Real-time Data Reporting

BRANFORD, Conn.–(BUSINESS WIRE)–Tangen Biosciences, Inc., today announced that the company and LabWare, Inc. agreed to enter into an exclusive partnership whereby LabWare will distribute Tangen’s GeneSpark™ device as part of the LabWare’s Portable Disease Surveillance Lab kit in response to the COVID-19 pandemic. LabWare’s kit includes a mobile hot spot and a tablet computer connected …

May 5, 2020

BARDA Funds Tangen Biosciences’ Multi-Target Platform Technology Development and a New Contract for Point-of-Care COVID-19 Molecular Test

BRANFORD, Conn.–(BUSINESS WIRE)–Tangen Biosciences, Inc., an innovative developer of rapid, portable, and Point-of-Care diagnostics, today announced that the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded TangenTM the Second Option of a contract to develop a molecular diagnostic platform that can be used by the company to …

  • 1
  • 2